LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice
Pharmaceuticals March 23, 2025 Gregory Ian Robinson, Marta Gerasymchuk, Timur Zanikov et al. 4 citations
Background/Objectives: Liver inflammatory diseases are a major global health burden and are often exacerbated by inflammation driven by lipopolysaccharides (LPS) through toll-like receptor 4 signaling. This study evaluates the anti-inflammatory effects of psilocybin and eugenol in an LPS-induced liver inflammation model in C57BL/6J mice. Methods: Mice were treated with psilocybin (0.88 mg/kg)...